Cargando…

Positron Emission Tomographic Imaging of Tumor Cell Death Using Zirconium-89-Labeled APOMAB® Following Cisplatin Chemotherapy in Lung and Ovarian Cancer Xenograft Models

PURPOSE: Early detection of tumor treatment responses represents an unmet clinical need with no approved noninvasive methods. DAB4, or its chimeric derivative, chDAB4 (APOMAB®) is an antibody that targets the Lupus associated antigen (La/SSB). La/SSB is over-expressed in malignancy and selectively t...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liapis, Vasilios, Tieu, William, Wittwer, Nicole L., Gargett, Tessa, Evdokiou, Andreas, Takhar, Prab, Rudd, Stacey E., Donnelly, Paul S., Brown, Michael P., Staudacher, Alexander H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Springer International Publishing 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8578059/ https://www.ncbi.nlm.nih.gov/pubmed/34231102 http://dx.doi.org/10.1007/s11307-021-01620-1

Ejemplares similares

Improved non-invasive positron emission tomographic imaging of chemotherapy-induced tumor cell death using Zirconium-89-labeled APOMAB®
por: Liapis, Vasilios, et al.
Publicado: (2020)

(89)Zr-pro-MMP-9 F(ab′)(2) detects colitis induced intestinal and kidney fibrosis
por: Dmochowska, Nicole, et al.
Publicado: (2020)

Enzyme mediated incorporation of zirconium-89 or copper-64 into a fragment antibody for same day imaging of epidermal growth factor receptor
por: Rudd, Stacey E., et al.
Publicado: (2021)

A new technique for the radiolabelling of mixed leukocytes with zirconium‐89 for inflammation imaging with positron emission tomography
por: Fairclough, M., et al.
Publicado: (2016)

Recent Advances in Zirconium-89 Chelator Development
por: Bhatt, Nikunj B., et al.
Publicado: (2018)

The Race for Hydroxamate-Based Zirconium-89 Chelators
por: Feiner, Irene V. J., et al.
Publicado: (2021)

Antibody drug conjugates: hitting the mark in pancreatic cancer?
por: Wittwer, Nicole L., et al.
Publicado: (2023)

The La antigen is over-expressed in lung cancer and is a selective dead cancer cell target for radioimmunotherapy using the La-specific antibody APOMAB®
por: Staudacher, Alexander H, et al.
Publicado: (2014)

Evaluation of macrocyclic hydroxyisophthalamide ligands as chelators for zirconium-89
por: Bhatt, Nikunj B., et al.
Publicado: (2017)

On the Versatility of Nanozeolite Linde Type L for Biomedical Applications: Zirconium-89 Radiolabeling and In Vivo Positron Emission Tomography Study
por: Lacerda, Sara, et al.
Publicado: (2022)

In Vitro and In Vivo Characterization of (89)Zirconium-Labeled Lintuzumab Molecule
por: Allen, Kevin J. H., et al.
Publicado: (2022)

An anti-mesothelin targeting antibody drug conjugate induces pyroptosis and ignites antitumor immunity in mouse models of cancer
por: Wittwer, Nicole L, et al.
Publicado: (2023)

Zirconium-89-labelled rituximab PET-CT in orbital inflammatory disease
por: Laban, Kamil G., et al.
Publicado: (2019)

Zirconium-89 labelled rituximab PET-CT imaging of Graves’ orbitopathy
por: de Keizer, Bart, et al.
Publicado: (2019)

Exploring the Potential of Zirconium-89 in Diagnostic Radiopharmaceutical Applications: An Analytical Investigation
por: Mostafa, Ahmed M. A., et al.
Publicado: (2023)

Zirconium tetraazamacrocycle complexes display extraordinary stability and provide a new strategy for zirconium-89-based radiopharmaceutical development
por: Pandya, Darpan N., et al.
Publicado: (2017)

Immuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?
por: Jauw, Yvonne W. S., et al.
Publicado: (2016)

Novel Chelating Agents for Zirconium-89-Positron Emission Tomography (PET) Imaging: Synthesis, DFT Calculation, Radiolabeling, and In Vitro and In Vivo Complex Stability
por: Kang, Chi Soo, et al.
Publicado: (2022)

Promising Performance of 4HMS, a New Zirconium-89 Octadendate Chelator
por: Alnahwi, Aiman H., et al.
Publicado: (2020)

APOMAB®, a La-Specific Monoclonal Antibody, Detects the Apoptotic Tumor Response to Life-Prolonging and DNA-Damaging Chemotherapy
por: Al-Ejeh, Fares, et al.
Publicado: (2009)

Zirconium-89 Labeled Antibodies: A New Tool for Molecular Imaging in Cancer Patients
por: van de Watering, Floor C. J., et al.
Publicado: (2014)

Evaluation of (89)Zr-pertuzumab in Breast Cancer Xenografts
por: Marquez, Bernadette V., et al.
Publicado: (2014)

Therapeutic targeting of tumor hypoxia and necrosis with antibody α-radioconjugates
por: Staudacher, Alexander H, et al.
Publicado: (2018)

(89)Zr-Immuno-Positron Emission Tomography in Oncology: State-of-the-Art (89)Zr Radiochemistry
por: Heskamp, Sandra, et al.
Publicado: (2017)

In Vivo Integrity and Biological Fate of Chelator-Free Zirconium-89-Labeled Mesoporous Silica Nanoparticles
por: Chen, Feng, et al.
Publicado: (2015)

Image reconstruction for a rotating positron tomograph
por: Townsend, D, et al.
Publicado: (1982)

Usefulness of Positron Emission Tomographic Studies for Gliomas
por: MIYAKE, Keisuke, et al.
Publicado: (2016)

Bone marrow cell homing to sites of acute tibial fracture: (89)Zr-oxine cell labeling with positron emission tomographic imaging in a mouse model
por: Asiedu, Kingsley O., et al.
Publicado: (2018)

Coronary Plaque Morphology and the Anti-Inflammatory Impact of Atorvastatin: A Multicenter (18)F-Fluorodeoxyglucose Positron Emission Tomographic/Computed Tomographic Study
por: Singh, Parmanand, et al.
Publicado: (2016)

Preparation of Zirconium-89 Solutions for Radiopharmaceutical Purposes: Interrelation Between Formulation, Radiochemical Purity, Stability and Biodistribution
por: Larenkov, Anton, et al.
Publicado: (2019)

Rational Design, Synthesis and Preliminary Evaluation of Novel Fusarinine C-Based Chelators for Radiolabeling with Zirconium-89
por: Zhai, Chuangyan, et al.
Publicado: (2019)

Molecular Imaging of Inflammation in a Mouse Model of Atherosclerosis Using a Zirconium-89-Labeled Probe
por: Ahmed, Mona, et al.
Publicado: (2020)

The RNA‐binding protein La/SSB associates with radiation‐induced DNA double‐strand breaks in lung cancer cell lines
por: Staudacher, Alexander H., et al.
Publicado: (2021)

18-Fluoride labeled sodium fluoride positron emission tomography with computer tomography: the impact of pretreatment staging in intermediate- and high-risk prostate cancer
por: Harley, Simon JD., et al.
Publicado: (2018)

Engineering Intrinsically Zirconium‐89 Radiolabeled Self‐Destructing Mesoporous Silica Nanostructures for In Vivo Biodistribution and Tumor Targeting Studies
por: Goel, Shreya, et al.
Publicado: (2016)

Noise-Induced Variability of Immuno-PET with Zirconium-89-Labeled Antibodies: an Analysis Based on Count-Reduced Clinical Images
por: Jauw, Yvonne W. S., et al.
Publicado: (2018)

In Vitro and In Vivo Comparison of 3,2-HOPO Versus Deferoxamine-Based Chelation of Zirconium-89 to the Antimesothelin Antibody Anetumab
por: Roy, Jyoti, et al.
Publicado: (2021)

p-Isothiocyanatobenzyl-desferrioxamine: a new bifunctional chelate for facile radiolabeling of monoclonal antibodies with zirconium-89 for immuno-PET imaging
por: Perk, Lars R., et al.
Publicado: (2009)

The AX-PET experiment: A demonstrator for an axial Positron Emission Tomograph
por: Bolle, E, et al.
Publicado: (2013)

(89)Zirconium-labelled girentuximab ((89)Zr-TLX250) PET in Urothelial Cancer Patients (ZiPUP): protocol for a phase I trial of a novel staging modality for urothelial carcinoma
por: Al-Zubaidi, Mohammed, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_p3p59v0i6q6p85qbqmuf1kvi8d